Brief: Abionyx Pharma- Results From Phase 3 Of Apoa-I Study Are Positive For Co

Abionyx Pharma SA

16/02/2024 07:24

Feb 16 (Reuters) - Abionyx Pharma SA  ABNX.PA :
    * ABIONYX PHARMA: CLARIFICATION ABOUT CLINICAL RESULTS FROM
THE
PHASE 3 OF APOA-I STUDY, CSL112
    * INTENDS TO CLARIFY THAT PHASE 3 CLINICAL RESULTS FOR
CSL112 ARE
EXTREMELY POSITIVE FOR COMPANY'S DEVELOPMENT AND FUTURE
    * CONFIRMS COMPANY'S SUCCESSFUL STRATEGIC REPOSITIONING 4
YEARS
AGO OUTSIDE FIELD OF CARDIOVASCULAR DISEASES
    * CONFIRMS SAFETY AND TOLERABILITY OF A TREATMENT WITH
APOA-1 IN
AN UNPRECEDENTED CLINICAL TRIAL INVOLVING 18,000 PATIENTS

Source text for Eikon:  urn:newsml:reuters.com:*:nBwc0J6Bxa
Further company coverage:  ABNX.PA 

 (Gdansk Newsroom)
 ((gdansknewsroom@thomsonreuters.com; + 48 58 7785110;))